Want to see TEM full AI Analyst Report?
Tempus AI, Inc. Class A (TEM) AI Stock Analysis
Tempus AI, Inc. Class A
(NASDAQ:TEM)
The score is held back primarily by weak financial fundamentals (ongoing losses, negative operating/free cash flow, and elevated leverage). Offsetting this, the stock’s technical setup is strong with a clear uptrend, and the latest earnings call was notably positive with raised guidance and multi-year collaboration tailwinds. Valuation remains challenging due to negative earnings and no dividend support.
Tempus AI, Inc. Class A Key Performance Indicators (KPIs)
Net Revenue by SegmentBreaks down the company’s revenue across its business lines (for example clinical sequencing and analytics, pharma partnerships, software/subscriptions, and research services). Reveals which segments drive growth, which are higher-margin or recurring, and whether revenue depends on a few large contracts or one-time projects — key for judging sustainability, profit potential, and exposure to reimbursement or partner risks.
Diagnostic revenue is the clear growth engine after a sharp inflection in early 2025, shifting Tempus toward a highly concentrated, rapidly scaling business mix. That acceleration suggests successful commercialization or large contract wins, but raises dependency risk if Diagnostic growth stalls or margins compress. Data & Applications is smaller, growing with more quarter-to-quarter volatility, so investors should focus on Diagnostic retention, margin sustainability, and customer concentration to judge whether the top-line surge is durable or transient.
The FlyTempus AI, Inc. Class A (TEM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $13.41B
- Dividend Yield
- ―
- Average Volume (3M)
- 7.11M
- Price to Earnings (P/E)
- -72.0
- Beta (1Y)
- 2.91
- Revenue Growth
- 36.56%
- EPS Growth
- 10.59%
- Country
- US
- Employees
- 3,800
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
Tempus AI, Inc. Class A Business Overview & Revenue Model
Company Description
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytic...
How the Company Makes Money
Tempus AI primarily makes money through (1) selling diagnostic and testing services and (2) monetizing its data and analytics capabilities with life sciences partners. 1) Clinical/diagnostic testing revenue: Tempus generates revenue by providing mole...
Tempus AI, Inc. Class A Earnings Call Summary
The call was strongly positive, led by 23% total revenue growth, 33% data and applications growth, 32% oncology volume growth, major multiyear collaborations, positive adjusted EBITDA, raised revenue guidance, and expanding data-platform scale. The principal challenges were the hereditary business lapping unusually high prior growth, reimbursement dependence, Personalis' current losses and delayed MRD sales-force expansion, and the limited scale expected from the clinical trial matching and CRO businesses. Highlights significantly outweighed the lowlights.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management increased guidance to $1.60 to $1.6 billion in 2026 and continues to expect 2026 adjusted EBITDA to be approximately $65 million; it said long term 25% growth is achievable, hereditary unit growth rates have returned to low double digits, oncology ASP is expected to receive about $80 million of uplift in 2027, and the BMS agreements are expected to generate $193 million of additional data and applications revenue over the next approximately 5 years.
Tempus AI, Inc. Class A Financial Statement Overview
Summary
Revenue scale is strong (~$1.51B TTM) with healthy gross margin (~64%) and improving losses versus 2024, but profitability and cash generation remain weak (EBIT margin ~-9%, net margin ~-13%, operating cash flow ~-$108M and free cash flow ~-$151M TTM). Leverage is also high (debt-to-equity ~2.9x), limiting flexibility if losses persist.
Income Statement
38NegativeBalance Sheet
34NegativeCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.51B | 1.27B | 693.40M | 531.82M | 320.67M | 257.85M |
| Gross Profit | 972.95M | 797.90M | 381.11M | 286.18M | 130.19M | 83.64M |
| EBITDA | -31.63M | -118.51M | -610.42M | -133.33M | -236.85M | -219.52M |
| Net Income | -189.29M | -245.03M | -705.81M | -214.12M | -289.81M | -259.19M |
Balance Sheet | ||||||
| Total Assets | 2.45B | 2.27B | 926.12M | 564.05M | 631.36M | 531.35M |
| Cash, Cash Equivalents and Short-Term Investments | 637.35M | 755.00M | 448.26M | 197.57M | 302.94M | 277.69M |
| Total Debt | 1.43B | 1.33B | 468.09M | 488.14M | 433.03M | 238.95M |
| Total Liabilities | 1.95B | 1.78B | 869.78M | 1.95B | 1.76B | 1.34B |
| Stockholders Equity | 500.40M | 491.33M | 56.34M | -1.38B | -1.13B | -807.49M |
Cash Flow | ||||||
| Free Cash Flow | -150.63M | -245.35M | -211.17M | -248.95M | -186.58M | -223.75M |
| Operating Cash Flow | -108.37M | -218.09M | -189.04M | -214.34M | -168.20M | -211.98M |
| Investing Cash Flow | -49.40M | -398.36M | -130.39M | -40.31M | -57.94M | -21.72M |
| Financing Cash Flow | 92.53M | 884.12M | 494.33M | 117.55M | 251.39M | -2.04M |
Tempus AI, Inc. Class A Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TEM, the sentiment is Positive. The current price of 75.61 is above the 20-day moving average (MA) of 70.17, above the 50-day MA of 71.04, and above the 200-day MA of 57.02, indicating a bullish trend. The MACD of 1.37 indicates Negative momentum. The RSI at 57.66 is Neutral, neither overbought nor oversold. The STOCH value of 70.60 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TEM.
Tempus AI, Inc. Class A Risk Analysis
Tempus AI, Inc. Class A disclosed 108 risk factors in its most recent earnings report. Tempus AI, Inc. Class A reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksTempus AI, Inc. Class A Peers Comparison
Overall Rating
CERT62Neutral- TEM61Neutral
HTFL59Neutral
HCAT47Neutral
SOPH47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| CERT | 62Neutral | $1.66B | -25.01 | -6.66% | ― | 0.66% | -134.07% |
| TEM | 61Neutral | $14.19B | -72.01 | -40.86% | ― | 36.56% | 10.59% |
| HTFL | 59Neutral | $4.73B | -39.84 | -42.25% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HCAT | 47Neutral | $108.37M | -0.43 | -129.70% | ― | -7.54% | -143.41% |
| SOPH | 47Neutral | $588.23M | -6.39 | -132.79% | ― | 24.11% | 2.08% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TEM | Tempus AI, Inc. Class A | 75.61 | 3.52 | 4.88% | |
| HCAT | Health Catalyst | 1.59 | -1.37 | -46.28% | |
| CERT | Certara, Inc. | 11.09 | -0.18 | -1.60% | |
| SOPH | Sophia Genetics Sa | 6.97 | 2.23 | 47.05% | |
| BFRG | BullFrog AI Holdings, Inc. | 0.53 | -0.43 | -45.21% | |
| HTFL | HeartFlow, Inc. | 56.57 | 22.08 | 64.02% |
Tempus AI, Inc. Class A Corporate Events
Tempus AI Reports Third-Quarter Results and Growth
PositiveTempus AI, a healthcare technology company focused on applying artificial intelligence to precision medicine, provides diagnostics, data and applications, and clinical workflow tools, with a major focus on oncology and broader healthcare research. On...
Tempus AI Expands Neurology Data Partnership With Pathos
PositiveOn October 23, 2026, Tempus AI announced a series of agreements with Bristol-Myers Squibb and Pathos AI that significantly expand the use of Tempus’s de-identified multimodal real-world data and analytic tools in oncology and neurology. Under t...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026